Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events). $250M raised through 1.75% convertible senior notes due May 15, 2032.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $250M raised through 1.75% convertible senior notes due May 15, 2032
- Low 1.75% cash coupon limits financing cost, while senior unsecured debt increases leverage
- Initial conversion price approximately $24.65 per share, creating potential equity dilution
- Maximum 14,705,875 shares issuable upon conversion based on the initial maximum conversion rate
- Proceeds provide capital flexibility, but noteholders gain conversion and fundamental-change repurchase rights
Item 8.01 · Other Events
- $125.0M gross capital raise: $100.0M equity plus $25.0M convertible notes over-allotment
- 7,352,942 shares sold at $17.00, creating shareholder dilution
- Approximately $359.0M net proceeds, including $242.0M from convertible notes and $117.0M equity
- Proceeds intended to repay Hercules Capital debt, fund thyroid eye disease expansion studies, pipeline R&D, and working capital
- Convertible financing adds future dilution or repayment obligations while extending funding for development programs
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.